Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Accounts Payables: 2016-2025

Historic Accounts Payables for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $40.6 million.

  • Ultragenyx Pharmaceutical's Accounts Payables rose 12.73% to $40.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.6 million, marking a year-over-year increase of 12.73%. This contributed to the annual value of $38.8 million for FY2024, which is 7.97% down from last year.
  • Ultragenyx Pharmaceutical's Accounts Payables amounted to $40.6 million in Q3 2025, which was up 18.49% from $34.2 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Accounts Payables registered a high of $59.8 million during Q2 2024, and its lowest value of $15.6 million during Q3 2021.
  • Moreover, its 3-year median value for Accounts Payables was $41.0 million (2024), whereas its average is $43.1 million.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Accounts Payables skyrocketed by 152.50% in 2022 and then tumbled by 42.75% in 2025.
  • Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's Accounts Payables stood at $17.1 million in 2021, then spiked by 152.50% to $43.3 million in 2022, then dropped by 2.68% to $42.1 million in 2023, then fell by 7.97% to $38.8 million in 2024, then climbed by 12.73% to $40.6 million in 2025.
  • Its Accounts Payables was $40.6 million in Q3 2025, compared to $34.2 million in Q2 2025 and $47.5 million in Q1 2025.